AVAGE

LOE Approaching

tazarotene

NDATOPICALCREAM
Approved
Sep 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARɣ, but shows relative selectivity for RARβ, and RARɣ and may modify gene expression. The clinical significance of these findings…

Pharmacologic Class:

Retinoid

Indications (1)

Clinical Trials (5)

NCT05652881N/ARecruiting

Does Joint Lavage Reduce Intraarticular Inflammation in High-energy Tibial Pilon Fractures?

Started Jan 2023
40 enrolled
Post-traumatic; ArthrosisTibial FracturesPost-Traumatic Osteoarthritis of Ankle
NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
NCT04071756Phase 2Terminated

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
NCT03845257N/ATerminated

Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma

Started Feb 2019
14 enrolled
Obstructive Lung Diseases
NCT03606486N/ATerminated

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

Started Nov 2018
52 enrolled
High Grade Ovarian Serous AdenocarcinomaStage III Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8+7 more